This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Najmi, S. Articles by Wieder, R. Search for Related Content PubMed PubMed Citation Articles by Najmi, S. Articles by Wieder, R.

Flavopiridol Blocks Integrin-Mediated Survival in Dormant Breast Cancer Cells

¹ Division of Oncology/Hematology, Department of Medicine and ² The Cardiovascular Research Institute, University of Medicine and Dentistry of New Jersey-New Jersey Medical School, Newark, New Jersey

Requests for reprints: Robert Wieder, University of Medicine and Dentistry of New Jersey-New Jersey Medical School, Division of Medical Oncology, MSB I-596, 185 South Orange Avenue, Newark, NJ 07103. Phone: 973-972-4871; Fax: 973-972-2384; E-mail: wiederro{at}umdnj.edu.

Purpose: Breast cancer micrometastases in the bone marrow are resistant to chemotherapy. They can remain dormant for years before some begin to proliferate. We seek to understand survival mechanisms and develop targeted approaches to eliminating these cells.

Experimental Design: In an in vitro model of dormancy, basic fibroblast growth factor 2 (FGF-2), abundant in the bone marrow, inhibits the growth of well-differentiated cells in the 2- to 10-cell stage and up-regulates integrin ₅ß₁. Through this integrin, cells bind fibronectin, spread out, and acquire a survival advantage, partly through activation of the phosphatidylinositol 3-kinase/Akt pathway. We investigated the effects of Taxotere, flavopiridol, and mitogen-activated protein/extracellular signal-regulated kinase (ERK) kinase and p38 inhibitors on survival of dormant clones and that of flavopiridol on expression of integrins, adhesion strength, and phosphorylation of Akt, ERK 1/2, and p38.

Results: Dormant MCF-7 and T-47D cell clones were resistant to Taxotere concentrations 10-fold higher than needed to eliminate growing clones but were almost completely eradicated by 200 nmol/L flavopiridol. Flavopiridol caused a decrease in FGF-2–induced expression of integrins, including ₅ and ß₁, and decreased FGF-2–induced specific adhesion to fibronectin. It diminished Akt phosphorylation, but reexpression of active Akt was not sufficient to reverse dormant clone inhibition. Flavopiridol did not affect phosphorylation of ERK 1/2 and p38 but diminished total protein levels. Chemical inhibition of these pathways partially abrogated dormant clone survival.

Conclusions: Flavopiridol has pleiotropic effects on key targets involved with survival of dormant breast cancer cells and may represent a useful approach to eliminating cells dependent on multiple signal pathways for survival.

Key Words: flavopiridol • dormancy • breast cancer • integrins • fibronectin • FGF-2 • Akt